Gilrose Pharmaceuticals

Gilrose Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for pain and central nervous system (CNS) disorders. The company's lead candidate, GR-101, is a proprietary fixed-dose combination of ketamine and midazolam intended for the treatment of acute pain. By combining these two agents, Gilrose aims to provide potent analgesia while reducing the dissociative and psychotomimetic side effects often associated with ketamine monotherapy. The company's strategy involves repurposing and reformulating established drugs to address unmet medical needs with a focus on non-opioid pain management solutions.